BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...
BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzogo. It reiterates its guidance of generating $4 billion in total sales by 2027.
Both of Genzyme's products are indicated for the treatment ... of their plant cell technology platform with this lead drug to perhaps provide a more cost-effective therapy,” he says, adding ...
Genzyme continued to drive growth for Sanofi ... analysts predicting sales of several billion dollars a year for the drug. Sanofi said the consolidation of Bioverativ, the haemophilia specialist ...
BMS refiled quickly, but was given an FDA action date of 27 March 2021 ... for example in the wake of Sanofi’s takeover of Genzyme in 2011, which also included a CVR tied to the approval ...
Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology. Many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results